ArticleInfection and drug resistance2022
Prevalence of Carbapenem-Resistant
Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Pharmacokinetics, safety, and tolerability of HRS-8427, a novel anti-carbapenem-resistant cephalosporin, in healthy subjects.Antimicrobial agents and chemotherapy · 2026Trial
- Prevalence, clinical characteristics, and antibiotic resistance of carbapenem-resistant Klebsiella pneumoniae in a tertiary hospital in Türkiye (2023-2025).BMC microbiology · 2026Observational
- Phenotypic characteristics and carbapenemase genes in Klebsiella pneumoniae from patients at Upendra Devkota Memorial National Institute of Neurological and Allied Sciences, Kathmandu, Nepal.BMC infectious diseases · 2025Article
- Dissemination ofMicrobiology spectrum · 2025Article
- Real-world usage, effectiveness, and microbiological features of ceftazidime-avibactam in clinical practice in China.Frontiers in cellular and infection microbiology · 2025Observational
- In vitro Antibacterial Effect of Reduning Combined with Polymyxin on Carbapenem ResistantInfection and drug resistance · 2025Article
- Molecular epidemiology of carbapenem-resistant hypervirulentFrontiers in cellular and infection microbiology · 2025Article
- Article
- Molecular detection of OXA-48 and NDM-1 carbapenemase genes among clinical isolates of Klebsiella pneumoniae recovered from patients attending a private tertiary hospital in Southwestern Nigeria.BMC infectious diseases · 2024Article
- Genomic Profile of a Multidrug-Resistant Klebsiella pneumoniae Strain Isolated from a Urine Specimen.Current microbiology · 2024Article
- Risk Factors and Outcomes of Community-Acquired Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- The Global and Regional Prevalence of Hospital-Acquired Carbapenem-ResistantOpen forum infectious diseases · 2024Review
- Development and application of a nomogram model for the prediction of carbapenem-resistantMicrobiology spectrum · 2024Article
- Clinical and Molecular Characteristics of Patients with Bloodstream Infections Caused by KPC and NDM Co-Producing Carbapenem-ResistantInfection and drug resistance · 2024Article
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Article
- Clinical and Molecular Profile of Carbapenem ResistantInfection and drug resistance · 2023Article
- Long Term Characteristics of Clinical Distribution and Resistance Trends of Carbapenem-Resistant and Extended-Spectrum β-LactamaseInfection and drug resistance · 2023Article
- Comparison of Epidemiological Characteristics Between ESBL and Non-ESBL Isolates of Clinically IsolatedInfection and drug resistance · 2023Article
- Clinical and resistance characterization of carbapenem-resistantAnnals of translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn this study, we analyzed the clinical distribution and drug resistance of carbapenem-resistant PATIENTS AND
methodsA total of 6328 strains of CRKP were collected from 2017 to 2019. The MIC was determined for the drug sensitivity test, and the experimental data were statistically analyzed using WHONET5.6.
resultsThe detection rate of CRKP increased annually from 13.4% in 2017 to 14.5% in 2018, and 14.6% in 2019. The ratio of males to females was approximately 2:1; 53.6% were elderly, 39% were adults, 4.8% were minors, and 2.5% were newborns. The specimens collected were mainly sputum (70.9%). The resistance rate of CRKP to carbapenems and other β-lactam antibiotics was found to be increasing, with resistance rates generally greater than 90%. The resistance rate to aminoglycoside antibiotics decreased yearly to approximately 50%, and the resistance rate to quinolones remained unchanged at approximately 80%. From 2017 to 2019, the resistance rate of CRKP in Hebei Province to various antibiotics was high, and the resistance rate to β-lactam antibiotics increased each year.
conclusionThe situation of CRKP resistance is severe in Hebei Province, China. The resistance rate to most antibiotics is very high and shows an upward trend. Among them, the resistance rate to polymyxin is low; however, few resistant strains do exist. MIC50 and MIC90 are higher than their MICs. It mainly causes lung infection in elderly men. This study is helpful to improve the diagnosis, treatment, and prevention of CRKP infection in our province.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.